Bluejay Diagnostics Adapts Symphony IL-6 Trial Design To Obtain More Patient Data; Plans To Modify Clinical Trials Design To Evaluate Symphony IL-6 As A Tool To Risk Stratify Hospitalized Sepsis Patients
Portfolio Pulse from Benzinga Newsdesk
Bluejay Diagnostics plans to modify the clinical trials design for its Symphony IL-6 test to obtain more patient data and evaluate its effectiveness in risk stratifying hospitalized sepsis patients.
May 19, 2023 | 11:02 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Bluejay Diagnostics is modifying the Symphony IL-6 trial design to gather more patient data, potentially improving the test's effectiveness in risk stratifying hospitalized sepsis patients.
The modification of the clinical trials design for Symphony IL-6 aims to obtain more patient data, which could lead to better evaluation of the test's effectiveness. This may result in improved risk stratification for hospitalized sepsis patients, potentially increasing the demand for the test and positively impacting Bluejay Diagnostics' stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100